Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantheus Holdings, Inc.LNTH · Entity 690 | Director | May 14, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantheus Holdings, Inc.
Report date May 14, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,118 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Tax withholding · Disposed 381 · Balance 27,118 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROGENICS PHARMACEUTICALS INC
Report date June 19, 2020 · Filed June 23, 2020
Section 16 reporting ended · disclosed 2020-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 1
1 source rowRow 1 · 2020-06-19 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-19 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F3: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2020-06-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-19 · Disposition to issuer · Disposed 16,393 · Balance 0 F3: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. F2: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A.
F2: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect.
F3: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger.
Y-mAbs Therapeutics, Inc.
Report date June 10, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,608 |
Reported balance
After 2024-06-10 transaction · row 1
1 source rowRow 1 · 2024-06-10 · Sale · Disposed 722 · Balance 1,608 F1: Nondiscretionary sale to cover tax liability associated with the vesting and settlement of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.015, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Nondiscretionary sale to cover tax liability associated with the vesting and settlement of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.015, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 18, 2026 20:35 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 4,137 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000205 · form4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,499 Read SEC document |
| May 14, 2026 Filed Jun 3, 2026 20:44 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 381 | $96.67 | $36,831.27 |
DisclosureSEC source: 0002064832-26-000219 · form4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,118 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,543 | $0.00 Strike: $78.81 | $0.00 |
DisclosureSEC source: 0001062993-25-009688 · form4.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,543 Underlying: Common Stock · 4,543 shares Expires 2035-05-14 Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:37 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009688 · form4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,362 Read SEC document |
| May 09, 2025 Filed May 13, 2025 20:07 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 396 | $81.74 | $32,369.04 |
DisclosureSEC source: 0001062993-25-009231 · form4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,825 Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:56 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 100 | $97.78 | $9,778.00 |
DisclosureSEC source: 0000950170-24-097147 · ownership.xml · nonDerivative · entry 3 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,221 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:56 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,225 | $97.10 | $410,247.50 |
DisclosureSEC source: 0000950170-24-097147 · ownership.xml · nonDerivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,321 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.75 to $97.72, inclusive. The reporting person undertakes to provide to LNTH any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:56 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 11,175 | $96.23 | $1,075,370.25 |
DisclosureSEC source: 0000950170-24-097147 · ownership.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,546 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.75 to $96.74, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 19:54 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | SaleCommon Stock | 722 | $12.00 | $8,664.00 |
DisclosureSEC source: 0001104659-24-070533 · tm2417022-2_4seq1.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,608 F1 · shares: Nondiscretionary sale to cover tax liability associated with the vesting and settlement of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.015, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 302 | $77.88 | $23,519.76 |
DisclosureSEC source: 0000950170-24-060532 · ownership.xml · nonDerivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,721 Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:11 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,853 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0000950170-24-058831 · ownership.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,853 Underlying: Common Stock · 4,853 shares Expires 2034-05-09 Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:11 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-058831 · ownership.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,350 Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 18:02 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantEmployee Stock Option (right to buy) · Derivative | 13,950 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0001104659-23-070044 · tm2318348-4_4seq1.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,950 Underlying: Common stock · 13,950 shares Expires 2033-06-08 F2 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F3 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on each vesting date and are exercisable immediately upon vesting. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 18:02 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantCommon Stock | 2,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-070044 · tm2318348-4_4seq1.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,330 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2024, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc. on the vesting date. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:35 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,798 | $0.00 Strike: $99.38 | $0.00 |
DisclosureSEC source: 0000899243-23-012991 · doc4.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,798 Underlying: Common Stock · 3,798 shares Expires 2033-05-11 Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:35 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,012 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-012991 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,715 Read SEC document |
| May 08, 2023 Filed May 15, 2024 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 327 | $94.82 | $31,006.14 |
DisclosureSEC source: 0000950170-24-060532 · ownership.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,023 Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 13:21 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantNon-Employee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001104659-22-080791 · tm2221312-3_4seq1.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-07-14 F1 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F2 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service to Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting. Read SEC document |
| May 10, 2022 Filed May 12, 2022 21:25 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,277 | $58.19 | $74,308.63 |
DisclosureSEC source: 0000899243-22-017785 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,703 F1 · shares: The Company withheld 1,277 shares to satisfy tax withholding obligations resulting from the vesting of restricted stock units. Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:39 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 3,616 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017449 · doc4.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,616 Underlying: Common Stock · 3,616 shares Expires 2032-05-06 Read SEC document |
| May 06, 2022 Filed May 10, 2022 20:39 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017449 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,980 F1 · shares: The restricted stock units cliff vest on May 6, 2023. Read SEC document |
| May 06, 2022 Filed May 12, 2022 21:51 UTC Amendment | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 4,068 | $0.00 Strike: $64.20 | $0.00 |
DisclosureSEC source: 0000899243-22-017806 · doc4a.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,068 Underlying: Common Stock · 4,068 shares Expires 2032-05-06 F1 · shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · derivative.underlying_shares: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. F1 · balance_after: The Form 4 originally filed on May 10, 2022 inadvertently reported 3,616 options granted on May 6, 2022 due to an administrative error. The correct amount of options granted on May 6, 2022 is 4,068 and is being reported in this amendment. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:03 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantNon-Employee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $37.53 | $0.00 |
DisclosureSEC source: 0001104659-21-080833 · tm2118093-14_4seq1.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common stock · 16,000 shares Expires 2031-06-10 F1 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F2 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 8,513 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019271 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,800 Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:50 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 1,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-027275 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,287 F1 · kind: As previously disclosed, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable in the fourth quarter of 2020, as calculated by the Company on October 1, 2020. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 21:39 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022154 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,222 F1 · kind: As previously disclosed, including most recently in our Form 10-Q for the fiscal period ended June 30, 2020, the Board of Directors of the Company elected to receive all remaining compensation payable in 2020 in the form of time-based restricted stock units, rather than in cash. The transaction reported in this Form 4 reports the additional restricted stock units earned by the reporting person for the compensation payable through the third quarter of 2020, as finally calculated by the Company on August 10, 2020. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 16:47 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantNon-Employee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $48.67 | $0.00 |
DisclosureSEC source: 0001104659-20-076458 · a4.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common stock · 16,000 shares Expires 2030-06-23 F1 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F2 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:48 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 16,393 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001437749-20-013676 · rdgdoc.xml · derivative · entry 3 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,393 shares Expires 2029-12-13 F3 · price: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. F2 · derivative.exercise_date: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:48 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerStock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001437749-20-013676 · rdgdoc.xml · derivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2029-12-13 F2 · price: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F3 · price: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. F2 · derivative.exercise_date: At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the other terms of the option continue in effect. F3 · derivative.exercise_date: This option was originally scheduled to vest in annual installments over the five-year period beginning December 13, 2019 and became immediately vested upon the Merger. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 16:48 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | Disposition to issuerCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-013676 · rdgdoc.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:21 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,481 | Not disclosed Strike: $16.17 | Not disclosed |
DisclosureSEC source: 0000899243-20-017493 · doc4.xml · derivative · entry 3 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,481 Underlying: Common stock · 17,481 shares Expires 2029-12-13 F2 · price: Received in the Merger in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics for $5.01 per share. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:21 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 15,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-017493 · doc4.xml · nonDerivative · entry 2 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,481 F1 · price: Received in exchange for 50,000 shares of Progenics Pharmaceuticals, Inc. ("Progenics"), in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger"). Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 21:21 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 5,981 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-017493 · doc4.xml · nonDerivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,981 Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 15:14 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 16,393 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001562180-19-006144 · primarydocument.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,393 Underlying: Common Stock · 16,393 shares Expires 2029-12-13 F1 · derivative.exercise_date: This stock option becomes exercisable immediately on the date of grant. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 15:14 UTC | PROGENICS PHARMACEUTICALS INC PGNX · Entity 148291 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001562180-19-006143 · primarydocument.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-12-13 F1 · derivative.exercise_date: 5yr 20% On Vest beginning on 13-Dec-2019 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:18 UTC | Y-mAbs Therapeutics, Inc. YMAB · Entity 75095 | GrantNon-Employee Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $21.45 | $0.00 |
DisclosureSEC source: 0001104659-19-035672 · a4.xml · derivative · entry 1 Ber Gerard · CIK 0001762144 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-06-12 F1 · security: Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. F2 · derivative.exercise_date: The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.